Seroprevalence rate after one dose of varicella vaccine in infants

被引:26
作者
Kim, So Hee [1 ]
Lee, Hoan Jong [1 ]
Park, Su Eun [2 ]
Oh, Sung Hee [3 ]
Lee, Seong Yeon [4 ]
Choi, Eun Hwa [1 ,4 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 110769, South Korea
[2] Pusan Natl Univ, Coll Med, Dept Pediat, Pusan 609735, South Korea
[3] Hanyang Univ, Coll Med, Dept Pediat, Seoul 133791, South Korea
[4] Seoul Natl Univ, Bundang Hosp, Dept Pediat, Songnam, South Korea
关键词
Varicella vaccine; Fluorescent antibody to membrane antigen; Seroprevalence; ZOSTER VIRUS; IMMUNE-RESPONSES; ANTIBODY-RESPONSE; HEALTHY-CHILDREN; UNITED-STATES; SAFETY; ASSAYS; IMMUNOGENICITY; DECLINE;
D O I
10.1016/j.jinf.2010.04.001
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Live, attenuated varicella vaccine has been used since 1988 in Korea. However, varicella is still prevalent among both vaccinated and unvaccinated individuals, despite a relatively high level of immunization rate up to 80%. A recent report has demonstrated similar to 20% of primary vaccine failure rate after one dose of varicella vaccine using the fluorescent antibody to membrane antigen (FAMA) assay. Methods: The seroprevalence rate was determined using the FAMA and ELISA assays in 67 Korean infants following one dose of varicella vaccine. Positive fluorescence at a serum dilution of 1: 4 or greater was considered as seropositive. Results: The median age at vaccination was 12 months and the post-immunization sera were obtained on average 6.3 months (range 6 weeks-12 months) after vaccination. Among the 67 vaccinated infants, 56 (83.6%) were seropositive by FAMA assay while 30 (44.8%) were seropositive by ELISA. The geometric mean titers (GMTs) of the seropositive vaccinated infants (n = 56) were significantly lower than the GMTs of 9 individuals with a history of varicella (1:17.0 vs. 1:74.7, P = 0.001). Although there were no significant differences in seropositive rates according to intervals, there was a decreasing trend in the GMTs over time among the 56 seropositive recipients (r(2) = 0.154, P < 0.001). Conclusions: These data can be useful for optimizing the immunization strategy against varicella and should be confirmed by a prospective study including a large number of immunized infants. (c) 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 38 条
[1]  
BOGGERGOREN S, 1982, J INFECT DIS, V146, P260, DOI 10.1093/infdis/146.2.260
[2]   Loss of vaccine-induced immunity to varicella over time [J].
Chaves, Sandra S. ;
Gargiullo, Paul ;
Zhang, John X. ;
Civen, Rachel ;
Guris, Dalya ;
Mascola, M. P. H. Laurene ;
Seward, Jane F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (11) :1121-1129
[3]  
CHOI EH, 2008, KOREAN J PEDIAT INFE, V15, P12
[4]  
Cohen J.I., 2007, FIELDS VIROLOGY, V2, P2773
[5]   Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States [J].
Davis, MM ;
Patel, MS ;
Gebremariam, A .
PEDIATRICS, 2004, 114 (03) :786-792
[6]  
Gershon A A, 1994, Clin Diagn Virol, V2, P271, DOI 10.1016/0928-0197(94)90051-5
[7]  
Gershon A.A., 2004, Vaccines, P783
[8]  
Hahn Robert, 2007, MMWR Recomm Rep, V56, P1
[9]  
KANG JH, 1997, KOREAN J PEDIAT INFE, V4, P257
[10]  
Kann L, 2016, MMWR SURVEILL SUMM, V65, P1, DOI [10.15585/mmwr.ss6506a1, 10.15585/mmwr.ss6708a1]